Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 18 | 2022 | 839 | 1.490 |
Why?
|
| Pancreas Transplantation | 7 | 2021 | 71 | 1.230 |
Why?
|
| Intestinal Perforation | 1 | 2020 | 35 | 0.760 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 47 | 0.740 |
Why?
|
| Graft Survival | 10 | 2022 | 465 | 0.410 |
Why?
|
| Renal Insufficiency | 2 | 2020 | 121 | 0.290 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2004 | 25 | 0.250 |
Why?
|
| Postoperative Complications | 5 | 2020 | 1615 | 0.240 |
Why?
|
| Reperfusion Injury | 2 | 2013 | 320 | 0.230 |
Why?
|
| Graft Rejection | 6 | 2021 | 458 | 0.210 |
Why?
|
| Blood Glucose | 3 | 2014 | 631 | 0.200 |
Why?
|
| Rituximab | 1 | 2020 | 61 | 0.190 |
Why?
|
| Methotrexate | 1 | 2020 | 91 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 164 | 0.180 |
Why?
|
| Transplant Recipients | 1 | 2020 | 109 | 0.170 |
Why?
|
| Patient Selection | 2 | 2020 | 592 | 0.170 |
Why?
|
| Delayed Graft Function | 2 | 2022 | 39 | 0.160 |
Why?
|
| Immunosuppressive Agents | 5 | 2009 | 514 | 0.150 |
Why?
|
| Liver Transplantation | 2 | 2013 | 400 | 0.150 |
Why?
|
| Nephrectomy | 2 | 2009 | 103 | 0.140 |
Why?
|
| Male | 18 | 2021 | 37281 | 0.140 |
Why?
|
| Thrombocytopenia | 2 | 2008 | 122 | 0.140 |
Why?
|
| Insulin | 2 | 2012 | 617 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 581 | 0.140 |
Why?
|
| Heparin | 2 | 2008 | 205 | 0.130 |
Why?
|
| Middle Aged | 11 | 2020 | 21119 | 0.130 |
Why?
|
| Living Donors | 2 | 2009 | 160 | 0.130 |
Why?
|
| Kidney | 3 | 2022 | 945 | 0.120 |
Why?
|
| Kidney Diseases | 2 | 2009 | 307 | 0.120 |
Why?
|
| Liver Failure | 1 | 2013 | 27 | 0.120 |
Why?
|
| Benchmarking | 1 | 2013 | 91 | 0.120 |
Why?
|
| Retrospective Studies | 9 | 2022 | 7264 | 0.110 |
Why?
|
| Fatty Liver | 1 | 2013 | 97 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 136 | 0.110 |
Why?
|
| Antilymphocyte Serum | 2 | 2009 | 52 | 0.110 |
Why?
|
| Adult | 14 | 2022 | 21375 | 0.110 |
Why?
|
| Telemedicine | 1 | 2020 | 699 | 0.110 |
Why?
|
| Humans | 21 | 2022 | 68525 | 0.110 |
Why?
|
| Perioperative Care | 1 | 2013 | 100 | 0.110 |
Why?
|
| Hyperglycemia | 2 | 2014 | 158 | 0.100 |
Why?
|
| Biomarkers | 1 | 2014 | 1593 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2013 | 413 | 0.080 |
Why?
|
| Female | 15 | 2021 | 38015 | 0.080 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2008 | 7 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 1030 | 0.080 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2007 | 8 | 0.080 |
Why?
|
| Algorithms | 1 | 2013 | 1194 | 0.080 |
Why?
|
| Creatinine | 2 | 2004 | 243 | 0.070 |
Why?
|
| Cholestasis | 1 | 2007 | 90 | 0.070 |
Why?
|
| Treatment Outcome | 8 | 2014 | 7028 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 693 | 0.070 |
Why?
|
| Thrombosis | 1 | 2008 | 218 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2008 | 356 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 510 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2008 | 483 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2007 | 193 | 0.070 |
Why?
|
| Raffinose | 1 | 2004 | 28 | 0.060 |
Why?
|
| Allopurinol | 1 | 2004 | 36 | 0.060 |
Why?
|
| Ribonucleotides | 1 | 2004 | 26 | 0.060 |
Why?
|
| Organ Preservation Solutions | 1 | 2004 | 45 | 0.060 |
Why?
|
| Organ Preservation | 1 | 2004 | 69 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2004 | 145 | 0.060 |
Why?
|
| Adenovirus Infections, Human | 1 | 2003 | 4 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2004 | 201 | 0.060 |
Why?
|
| Adenosine | 1 | 2004 | 165 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 163 | 0.060 |
Why?
|
| Sirolimus | 1 | 2004 | 118 | 0.060 |
Why?
|
| Ribavirin | 1 | 2003 | 27 | 0.060 |
Why?
|
| Dogs | 1 | 2004 | 490 | 0.060 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2003 | 52 | 0.060 |
Why?
|
| Glutathione | 1 | 2004 | 343 | 0.050 |
Why?
|
| Aged | 5 | 2020 | 14842 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 58 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1174 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 626 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2003 | 211 | 0.050 |
Why?
|
| Acetylcysteine | 1 | 2004 | 296 | 0.050 |
Why?
|
| Smoking | 1 | 2009 | 1449 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2022 | 195 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2020 | 104 | 0.050 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2009 | 32 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1046 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2020 | 383 | 0.040 |
Why?
|
| Length of Stay | 2 | 2013 | 780 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1054 | 0.040 |
Why?
|
| Young Adult | 3 | 2013 | 5708 | 0.040 |
Why?
|
| Apoptosis | 1 | 2004 | 1640 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 2550 | 0.040 |
Why?
|
| Obesity | 1 | 2003 | 1074 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2014 | 2356 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2264 | 0.030 |
Why?
|
| Prognosis | 2 | 2013 | 2093 | 0.030 |
Why?
|
| Adolescent | 3 | 2013 | 8903 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 3256 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2014 | 72 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 144 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 180 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2012 | 25 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2014 | 330 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2013 | 3185 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 392 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 521 | 0.030 |
Why?
|
| Risk Factors | 2 | 2014 | 5719 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2013 | 267 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2012 | 161 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2013 | 621 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 1055 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 730 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1419 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 361 | 0.020 |
Why?
|
| Child | 2 | 2013 | 6400 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1341 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 563 | 0.020 |
Why?
|
| Hirudins | 1 | 2008 | 32 | 0.020 |
Why?
|
| Factor V | 1 | 2008 | 20 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2008 | 57 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 151 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 376 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2008 | 123 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2007 | 58 | 0.020 |
Why?
|
| Animals | 1 | 2004 | 20877 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 791 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 481 | 0.020 |
Why?
|
| Health Status | 1 | 2009 | 429 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 742 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 3702 | 0.020 |
Why?
|
| Platelet Count | 1 | 2005 | 100 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 4843 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 2077 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1745 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2003 | 55 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 334 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2003 | 127 | 0.010 |
Why?
|
| Liver | 1 | 2008 | 1118 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 648 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 539 | 0.010 |
Why?
|
| United States | 1 | 2013 | 7335 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2003 | 866 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 2222 | 0.010 |
Why?
|
| Infant | 1 | 2004 | 2891 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 4655 | 0.010 |
Why?
|